Literature DB >> 20148796

Drug classification: science, politics, both or neither?

Harold Kalant1.   

Abstract

Governments currently classify illicit drugs for various purposes: to guide courts in the sentencing of convicted violators of drug control laws, to prioritize targets of prevention measures and to educate the public about relative risks of the various drugs. It has been proposed that classification should be conducted by scientists and drug experts rather than by politicians, so that it will reflect only accurate factual knowledge of drug effects and risks rather than political biases. Although this is an appealing goal, it is inherently impossible because rank-ordering of the drugs inevitably requires value judgements concerning the different types of harm. Such judgements, even by scientists, depend upon subjective personal criteria and not only upon scientific facts. Moreover, classification that is meant to guide the legal system in controlling dangerous drug use can function only if it is in harmony with the values and sentiments of the public. In some respects, politicians may be better attuned to public attitudes and wishes, and to what policies the public will support, than are scientific experts. The problems inherent in such drug classification are illustrated by the examples of cannabis and of salvinorin A. They raise the question as to whether the classification process really serves any socially beneficial purpose.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148796     DOI: 10.1111/j.1360-0443.2009.02830.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  8 in total

1.  "I'm not afraid of those ones just 'cause they've been prescribed": perceptions of risk among illicit users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2012-03-13

Review 2.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

3.  Adverse psychosocial outcomes associated with drug use among US high school seniors: a comparison of alcohol and marijuana.

Authors:  Joseph J Palamar; Michael Fenstermaker; Dimita Kamboukos; Danielle C Ompad; Charles M Cleland; Michael Weitzman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-08-29       Impact factor: 3.829

4.  Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.

Authors:  Dirk W Lachenmeier; Jürgen Rehm
Journal:  Sci Rep       Date:  2015-01-30       Impact factor: 4.379

5.  Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.

Authors:  Celia J A Morgan; Louise A Noronha; Mark Muetzelfeldt; Amanda Feilding; Amanda Fielding; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2013-02-25       Impact factor: 4.153

6.  Toward an Improved Multi-Criteria Drug Harm Assessment Process and Evidence-Based Drug Policies.

Authors:  Veljko Dubljević
Journal:  Front Pharmacol       Date:  2018-08-20       Impact factor: 5.810

7.  Changes in cannabis policy and prevalence of recreational cannabis use among adolescents and young adults in Europe-An interrupted time-series analysis.

Authors:  Alexander Carl Gabri; Maria Rosaria Galanti; Nicola Orsini; Cecilia Magnusson
Journal:  PLoS One       Date:  2022-01-12       Impact factor: 3.240

8.  Toward a rational and ethical sociotechnical system of autonomous vehicles: A novel application of multi-criteria decision analysis.

Authors:  Veljko Dubljevic; George List; Jovan Milojevich; Nirav Ajmeri; William A Bauer; Munindar P Singh; Eleni Bardaka; Thomas A Birkland; Charles H W Edwards; Roger C Mayer; Ioan Muntean; Thomas M Powers; Hesham A Rakha; Vance A Ricks; M Shoaib Samandar
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.